Mission Therapeutics (United Kingdom)

Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control

Isaia Barbieri, Konstantinos Tzelepis, Luca Pandolfini et al. · Nature · 2017 · 1.1K citations · Full text

Hematological Malignancy, Mixed-phenotype Acute Leukemia, Promoter-bound Mettl3 +5

Targeting the m⁶A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication

Hannah M. Burgess, Daniel P. Depledge, Letitia Thompson et al. · Genes & Development · 2021 · 137 citations · Full text

Discovery of a Potent and Selective Covalent Inhibitor and Activity-Based Probe for the Deubiquitylating Enzyme UCHL1, with Antifibrotic Activity

Nattawadee Panyain, Aurélien Godinat, Thomas Lanyon‐Hogg et al. · Journal of the American Chemical Society · 2020 · 107 citations · Full text

Drug Target, Selective Uchl1 Probe, Chemical Biology +25

Assessing the lipophilicity of fragments and early hits

Paul N. Mortenson, Christopher W. Murray · Journal of Computer-Aided Molecular Design · 2011 · 106 citations

Inflammation, Lipid Analysis, Early Hits +4

Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity

Andrew A. Guirguis, Yaara Ofir-Rosenfeld, Kathy Knezevic et al. · Cancer Discovery · 2023 · 100 citations